{"id":26,"date":"2017-09-15T16:03:27","date_gmt":"2017-09-15T16:03:27","guid":{"rendered":"https:\/\/wordpress-dev.med.unc.edu\/millerlab\/?page_id=26"},"modified":"2018-08-18T11:57:18","modified_gmt":"2018-08-18T15:57:18","slug":"dynamic-profiling-of-the-glioma-kinome","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/research\/dynamic-profiling-of-the-glioma-kinome\/","title":{"rendered":"Dynamic profiling of the glioma kinome"},"content":{"rendered":"
\n

Targeted kinase inhibitors represent a promising alternative to standard cytotoxic treatments for gliomas, including glioblastoma (GBM).\u00a0 But use of brain-penetrant drugs in combinations designed to overcome compensatory resistance mechanisms will likely be necessary to improve outcomes. Preclinical studies can aid identification of effective drug combinations.<\/em><\/p>\n<\/header>\n

\n
\n

Project summary<\/h2>\n

We\u00a0investigate the molecular mechanisms of kinase inhibitor resistance using\u00a0genetically-engineered mouse<\/a>\u00a0(GEM) models and\u00a0human\u00a0patient-derived xenografts<\/a>\u00a0(PDX).<\/p>\n

In particular, we focus on the molecular mechanisms by which the kinome adapts to short- and long-term drug exposure.<\/p>\n

\n

Mechanistic studies use non-germline GEM (nGEM) and PDX culture systems<\/a> to:<\/p>\n

Examine how adaptive kinome changes contribute to kinase inhibitor resistance<\/h3>\n

Integrated proteomics and genomics analyses are critical for this work. \u00a0These include kinome profiling using multiplex inhibitor beads\u00a0and mass spectrometry<\/a> (MIB-MS) and\u00a0RNA<\/a>-seq to examine drug-induced changes in the kinome and kinase transcriptome.<\/p>\n

\"\"
PI3K inhibition with buparlisib (BKM120) induces dynamic, adapative kinome changes in murine TRP astrocytes as determined by MIB-MS over 4-48 h (A).\u00a0\u00a0Dynamics of select kinases illustrated 3 response types: sustained inhibition (pattern 1, blue), reactivation (pattern 2, green), and alternate pathway activation (pattern 3, red). Graphs show the first kinase listed.<\/figcaption><\/figure>\n

McNeill et al. \u00a0Neuro-oncology 19(11):1469 2017<\/a><\/p>\n

\n

Define the\u00a0kinome of human glioma model systems and tumors<\/h3>\n

We perform MIB-MS kinome and RNA-seq transcriptome profiling on established human glioma cell lines, PDX cultures, and human gliomas to identify kinase networks that may be useful for disease classification, improved molecular diagnostics, and development of predictive biomarkers for kinase inhibitor therapies.<\/p>\n<\/div>\n

\"\"
GBMs have heterogeneous kinomes. Heterogeneous kinome activity was evident in (A) established cell lines (ECL) and (B) tumor samples from human GBM patients. (C) Principal components analysis showed 2 kinome subtypes of human tumors (K1, K2). (D) K1 had hyperactivation relative to K2 (E) tumors. Kinases with \u22652x (red) or \u22640.4x (blue) relative MIB binding are indicated; other detected kinases (black). A waterfall plot shows the most differentially activated kinases (F). Kinases significantly (P < 0.05) enriched in K1 (black) and K2 (red) are indicated (*). Heterogeneous kinome activity was also evident in subcutaneous GBM PDX (G, Supplementary Figure S5C). Principal components analysis demonstrated that although variable, biologic replicates of subcutaneous GBM PDX were more similar to each other than to different PDX models (H).<\/figcaption><\/figure>\n
\n

McNeill et al. \u00a0Neuro-oncology 19(11):1469 2017<\/a><\/p>\n

\n

References<\/h2>\n
    \n
  1. McNeill RS, Stroobant EE, Smithberger E, Canoutas DA, Butler MK, Shelton AK, Patel SD, Limas JC, Skinner KR, Bash RE, Schmid RS, Miller CR.\u00a0 PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.\u00a0 PLoS One.\u00a0 13(7):e0200014 Jul 2018.\u00a0 PMID: 29975751<\/a>\u00a0 PMCID: PMC6033446<\/a><\/li>\n
  2. Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR. MerTK as a therapeutic target in glioblastoma.\u00a0 Neuro-oncology. 20(1):92-102 Jan 2018.\u00a0 PMID: 28605477<\/a> \u00a0PMCID:\u00a0 PMC5761530<\/a><\/li>\n
  3. McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.\u00a0 Neuro-oncology.\u00a0 19(11):1469-1480 Oct 2017.\u00a0 PMID: 28379424<\/a> \u00a0PMCID:\u00a0 PMC5737415<\/a><\/li>\n
  4. Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK. Combined kinase inhibitors of MEK1\/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.\u00a0 Neuro-oncology.\u00a0 19(11):1481-1493 Oct 2017.\u00a0 PMID: 28486691<\/a> \u00a0PMCID:\u00a0 PMC5737524<\/a><\/li>\n
  5. McNeill RS,\u00a0Vitucci M,\u00a0Wu J,\u00a0Miller CR.\u00a0 Contemporary murine models in preclinical astrocytoma drug development.\u00a0 Neuro-oncology.\u00a0 17(1):12-28 Jan 2015.\u00a0 PMID:\u00a025246428<\/a>\u00a0 PMCID:\u00a0PMC4483055<\/a><\/li>\n
  6. McNeill RS,\u00a0Schmid RS,\u00a0Bash RE,\u00a0Vitucci M,\u00a0White KK,\u00a0Werneke AM,\u00a0Constance BH,\u00a0Huff B,\u00a0Miller CR.\u00a0 Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.\u00a0 Journal of Visualized Experiments.\u00a0 90:e51763 Aug 2014.\u00a0 PMID:\u00a025146643<\/a><\/li>\n
  7. Vitucci M, Karpinich NO,\u00a0Bash RE,\u00a0Werneke AM,\u00a0Schmid RS,\u00a0White KK,\u00a0McNeill RS,\u00a0Huff B, Wang S, Van Dyke T,\u00a0Miller CR.\u00a0 Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. \u00a0Neuro-oncology.\u00a0 15(10):1317-1329 Oct 2013.\u00a0 PMID:\u00a023814263<\/a>\u00a0 PMCID:\u00a0PMC3779038<\/a><\/li>\n<\/ol>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Targeted kinase inhibitors represent a promising alternative to standard cytotoxic treatments for gliomas, including glioblastoma (GBM).\u00a0 But use of brain-penetrant drugs in combinations designed to overcome compensatory resistance mechanisms will likely be necessary to improve outcomes. Preclinical studies can aid identification of effective drug combinations. Project summary We\u00a0investigate the molecular mechanisms of kinase inhibitor resistance … Read more<\/a><\/p>\n","protected":false},"author":68816,"featured_media":0,"parent":10,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-26","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/26","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/users\/68816"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/comments?post=26"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/26\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/10"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/media?parent=26"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}